Dual-Modality Monitoring of Targeted Intraarterial Delivery of Mesenchymal Stem Cells After Transient Ischemia

Piotr Walczak, MD; Jian Zhang, MD; Assaf A. Gilad, PhD; Dorota A. Kedziorek, MD; Jesus Ruiz-Cabello, PhD; Randell G. Young, DVM; Mark F. Pittenger, PhD; Peter C.M. van Zijl, PhD; Judy Huang, MD; Jeff W.M. Bulte, PhD

Background and Purpose—In animal models of stroke, functional improvement has been obtained after stem cell transplantation. Successful therapy depends largely on achieving a robust and targeted cell engraftment, with intraarterial (IA) injection being a potentially attractive route of administration. We assessed the suitability of laser Doppler flow (LDF) signal measurements and magnetic resonance (MR) imaging for noninvasive dual monitoring of targeted IA cell delivery.

Methods—Transient cerebral ischemia was induced in adult Wistar rats (n=25) followed by IA or intravenous (IV) injection of mesenchymal stem cells (MSCs) labeled with superparamagnetic iron oxide. Cell infusion was monitored in real time with transcranial laser Doppler flowmetry while cellular delivery was assessed with MRI in vivo (4.7T) and ex vivo (9.4T).

Results—Successful delivery of magnetically labeled MSCs could be readily visualized with MRI after IA but not IV injection. IA stem cell injection during acute stroke resulted in a high variability of cerebral engraftment. The amount of LDF reduction during cell infusion (up to 80%) was found to correlate well with the degree of intracerebral engraftment, with low LDF values being associated with significant morbidity.

Conclusions—High cerebral engraftment rates are associated with impeded cerebral blood flow. Noninvasive dual-modality imaging enables monitoring of targeted cell delivery, and through interactive adjustment may improve the safety and efficacy of stem cell therapy. (Stroke. 2008;39:000-000.)

Key Words: laser Doppler flow ■ MRI ■ stroke ■ stem cells ■ transplantation

Recent discoveries in the field of stem cell research have opened new avenues for the therapy of complex diseases, particularly those of the central nervous system. It has been shown repeatedly in animal models that neurological deficits can be diminished by the introduction of therapeutic cells.1,2 These observations in animal models provided the basis for the first clinical trials in Parkinson disease3 and stroke patients.4–6

Stroke is a leading cause of serious, long-term disability, and survivors of ischemic insults have little effective treatment available. Although evidence of the beneficial effects of stem cells in animal stroke models is growing, the mechanisms behind the improvements are still unclear.7 Some investigators have postulated that functional improvement is related to trophic support, which promotes survival of challenged neurons in the penumbra,8 inducing myelination and neural plasticity,9 or is attributable to other factors, such as neoangiogenesis.10 Other researchers suggest that functional improvement is related to both neuronal differentiation and integration.11 In any case, demonstration of therapeutic effects have been modest to date, and clearly, optimization of robust engraftment and detailed characterization of basic cellular events, such as migration, differentiation, and graft-host interactions, remains essential.

One obstacle that has hampered the advancement of stem cell transplantation is inadequate methodology to allow stem cell characterization in living organisms. Several techniques for noninvasive in vivo cellular imaging have been developed, including intravital multi-photon microscopy,12,13 bioluminescence,14 PET,15 and MRI.16–18 In stroke, MRI has been used in rats to demonstrate that embryonic stem cells19 or neural stem cells20 grafted into the hemisphere contrasted...
eral to the ischemic lesion migrate along white matter tracts and populate the border zone of the ischemic brain lesion. MRI has also depicted migration of neural progenitors from the cisterna magna to the ischemic lesion.\textsuperscript{21,22}

Because of their relatively low immunogenicity and easy way of isolation, mesenchymal stem cells (MSCs) have recently gained interest as potential cell types for improvement of clinical outcome in neurodegenerative diseases, including stroke.\textsuperscript{5,23,24} However, the most optimal route of injection is at present unknown. Brain intraparenchymal injections can be targeted toward the lesion but are invasive, and multiple injections may be required to cover the entire area of the stroke lesion. Intracerebroventricular (ICV) injection of cells enables widespread cerebral engraftment of cells along the entire neuroaxis, but is limited for lesions located more remote from the ventricles. Intravenous (IV) injection is least invasive but may lead to low numbers of engrafted cells at the lesion and major trapping in the lung, liver, and spleen.\textsuperscript{25,26} Intracarotid (IA) injection, on the other hand, may be used to bypass the initial uptake by the systemic organs and deliver larger numbers of cells directly to the ischemic lesion, once vessels are reperfused. Clinical translation of any of these stem cell delivery strategies mandates the use of noninvasive monitoring techniques. In this study, we therefore investigated the feasibility of monitoring intraarterial cell delivery after transient ischemia with laser Doppler flow (LDF) measurements of cerebral blood flow in conjunction with MRI cell tracking.

**Materials and Methods**

**Cell Culture and Labeling**
MSCs derived from the bone marrow of adult Fisher 344 rats were isolated as previously described\textsuperscript{27} and expanded in vitro using α-MEM/F12 medium containing 10% fetal bovine serum. Before transplantation, cells were magnetically labeled with Feridex (Berlex Imaging) mixed with the transfection agent poly-L-lysine (Sigma-Aldrich), added at 25 μg Fe/mL to the cell cultures for a 24-hour incubation.\textsuperscript{28} The iron content (pg Fe/cell) was determined using a custom-made probe, equipped with a 20-mm surface coil. In vivo imaging was performed using a Bruker 4.7T horizontal bore magnet. The in vivo imaging parameters were: (1) a T2-weighted 3D spin echo (SE) sequence with repetition time (TR)=1300 ms, echo time (TE)=98 ms, number of averages (NAV)=2, field of view (FOV)=34×22×11 mm, matrix=128×64×32, and resolution=266×343×350 μm; and (2) a 3D T2*-weighted gradient echo (GRE) sequence with TR=300 ms, TE=5 ms, NAV=4, FOV=10×16×4 mm, matrix=128×128×12, and resolution=83×125×333 μm. The first imaging session was performed before the MCAO/cell infusion procedure, and the second was performed between 2 and 24 hours after the procedure. After in vivo MRI, brains were transcardially perfused with 0.1 mol/L PBS containing 4% paraformaldehyde, and the brains were removed for high-resolution ex vivo imaging and further histological analysis.

**Histopathology**
Brains were cryopreserved in 20% sucrose for 24 hours, and then sectioned at 20 μm using a cryostat. To determine the efficiency of cell labeling as well as to correlate the histopathology with MRI, tissue preparations were processed for Prussian blue\textsuperscript{29} for Feridex iron and immunohistochemistry for BrdU (rat monoclonal antibody OBT0030, 1:400; Accurate Chemicals, as primary, and goat-anti rat 488, A11008, 1:300, Molecular Probes, as secondary). Microscopic analysis was performed using Olympus X51 and IX71 epifluorescence microscopes equipped with an Olympus DP-70 digital acquisition system. MRI data sets were processed with Amira 3.1 software (Mercury Computer Systems).

**Results**
Magnetic cell labeling of MSCs was highly efficient, with nearly all cells being labeled. Prussian blue staining (Figure 1A) demonstrated numerous iron-containing vesicles throughout the cellular cytoplasm. The average amount of Feridex labeling was 15 to 20 pg of iron per cell. After BrdU pulsing before transplantation, the colabel BrdU was detected in nearly all labeled and unlabeled cells. The MTS assay demonstrated minimal changes after Feridex labeling, with proliferation values ≥90% that of unlabeled cells at 24 hours after labeling.

**LDF Monitoring of Cell Delivery**
Intraluminal occlusion of MCAO resulted in a consistent reduction of CBF to about 30% of baseline (Figure 2). This level was maintained throughout a 2-hour period in all animals tested. After removal of the suture and reperfusion,
CBF returned to near-baseline levels. The delivery of $1 \times 10^6$ MSCs into the carotid artery ipsilateral to the ischemic lesion was initiated 30 minutes into the reperfusion period, and resulted in a high variability of cell engraftment. In 3 animals (17%), there was no change in LDF signal (Figure 2, black line) with no cells detectable in the brain by MRI (Figure 3a and 3b) and histology (results not shown). In 8 animals (47%), the LDF signal drop was moderate (10% to 30%; Figure 2, blue line), with moderate cell engraftment (Figure 3c and 3d). In 6 animals (35%), the injection caused a significant (80% to 90%) reduction in LDF signal (Figure 2, red line) and a rapid death within 2 to 4 hours in 4 animals. Although the MCAO procedure itself can lead to a high mortality we observed, that in control, nontransplanted animals that underwent MCAO the mortality during the first 48 hours was about 7% as compared to 67% in the MCAO-cell transplant group.

MR Monitoring of Targeted Cell Delivery
In vivo T2*-weighted MRI (Figure 3c and 3e) detected the engraftment of labeled cells within the right ICA vascular territory, as represented by the presence of strong signal voids, which was further confirmed by high-resolution ex vivo MRI (Figure 3d and 3f). Engraftment of injected MSCs was found to occur primarily throughout the right ICA vascular territory and only occasionally in the contralateral hemisphere (Figure 3c through 3g), indicating that cells engrafted during the first pass without systemic circulation. These findings were further confirmed by Prussian blue staining and immunofluorescent anti-BrdU microscopy (Figure 4a and 4b). One day after cell infusion, iron and BrdU-positive cells were located within the cerebral capillary bed (Figure 4a and 4b). At later time points (10 days after transplantation), BrdU-positive cells were found to have entered the parenchyma of the cerebral cortex (Figure 4c). In contrast to the IA cell delivery, IV injection resulted in undetectable MRI levels of cell engraftment (Figure 3g), with very few cells present in the brain after histological evaluation. While the amount of iron within labeled MSCs generated sufficient contrast for cell detection on T2*-weighted MR images (with a T2* sequence being the most sensitive to magnetic field disturbances caused by iron-labeled cells), T2-weighted imaging (less sensitive to iron) allowed a proper visualization of the ischemic brain tissue (Figure 5).

Discussion
We have demonstrated that IA infusion of MSCs in rats during the acute stage of stroke results in a high variability of targeted cellular delivery in the brain. The results of our study...
suggest that monitoring of cell delivery and engraftment is possible using both LDF measurements and MRI.

Evidence for a positive outcome of cell-based therapies is now mounting in animal stroke models. For instance, bone marrow–derived mesenchymal cells implanted 24 hours after MCAO in rats led to behavioral improvements, and grafted cells were detected throughout the middle cerebral artery (MCA) territory up to 2 weeks after grafting. In a similar experiment, grafted mesenchymal cells led to functional improvements that mediated remyelination and synaptic plasticity enhancement. Initial clinical trials of therapeutic IA stem cell transplantation have now been performed. In stroke patients, autologous bone marrow–derived mononuclear cells were infused into the MCA ipsilateral to the stroke lesion.

Now that clinical trials are being performed in stroke patients, it is of key importance to design and establish safe and efficient methods to deliver cells to the sites of ischemic brain damage. Among the available routes for intracerebral cell delivery are intraparenchymal, ICV, IV, and IA. Intraparenchymal, stereotactic cell injection is based on insertion of a needle and infusion of the cells into the brain parenchyma. Although this method provides precision with regard to the graft placement and there is some evidence on directed cell migration toward the ischemic site, there is usually a poor cell distribution throughout the lesion, as a result of the limited migratory potential of cells in the adult brain. Inadequate cell migration can be addressed by performing multiple injections; however, this in turn enhances the risk of brain injury and can lead to nonuniform cell distribution with the risk of graft malfunction. In contrast, IV delivery is a relatively easy and noninvasive procedure, allowing a broad distribution of cells, and enabling exposure of cells to chemoattractant signals (originating from the lesion) that can selectively accumulate them within the target tissue. However, IV injection leads to an initial random dispersion of cells throughout the body, with cells accumulating in trapping and filtering organs such as the lungs, liver, and spleen. Only a small amount of cells may be able to reach the target brain lesion, and thus, the cell dose must be appropriately adjusted. Indeed, when we performed IV injections, we could only detect trace quantities of cells within the brain on histology; the low levels of engrafted cells could not be detected by MRI. The advantage of ICV injection is that cells have access to a larger surface of the brain, although the success of this approach depends even more on the robust migratory properties of grafted cells, their appropriate navigation while in the CSF, and on crossing the blood-CSF barrier with subsequent penetration into the parenchyma. In addition, access to the ventricular system in humans is highly

Figure 3. MR images of intracerebral cell engraftment after IA (A–F, H) and IV (G) injection. MSCs appear as hypointense spots on T2*-weighted images. A, In vivo and (B) ex vivo MR images of an animal corresponding to the black line in Figure 2. No brain engraftment can be observed. In vivo (C) and ex vivo (D) MR images of an animal corresponding to the blue line in Figure 2. A moderate brain engraftment can be seen with some cells entering the other hemisphere. In vivo (E) and ex vivo (F) MR images of an animal corresponding to the red line in Figure 2. A massive engraftment can be observed, but the cell distribution is limited to the right hemisphere perfused by the right carotid artery used for injection. G, No engraftment could be detected after IV injection. H, 3D reconstruction of cellular distribution in the brain of example shown in E and F. Cells distributed widely throughout the right brain hemisphere, with a prevalence for the area directly fed by the right internal carotid artery; the territory of the anterior and posterior cerebral arteries also exhibit significant engraftment. Very few cells were detected in the contralateral (left) hemisphere, suggesting that cells did not circulate systemically before arriving at their final location.

Figure 4. Histopathologic detection of engrafted MSCs. Prussian blue staining (A) and immunohistochemistry anti-BrdU (B) at early time points (1 day) demonstrate single cells found within the capillaries (arrow heads) throughout the ipsilateral brain hemisphere. Ten days after transplantation BrdU-positive cells were found within the brain parenchyma, indicating active migration across vessel walls (C, arrows). Scale bar=40 μm.
invasive and requires drilling a hole in the skull for placement of a ventriculostomy catheter.

In contrast, IA cell delivery provides the opportunity to target the entire ischemic lesion within the relevant vascular territory after transient ischemia. Furthermore, IA delivery of therapeutic cells into the brain is clinically relevant, because percutaneous transfemoral catheterization of selected intracranial arteries using microcatheters is already commonly used in clinical practice.

Cerebral ischemia results from transient or permanent vascular occlusions; in the case of a transient occlusion cells may be targeted toward the entire lesion. However, in the case of a permanent occlusion they will be distributed only throughout the penumbra region.

The mechanisms regulating intracerebral engraftment of infused stem cells are complex and depend on the physical and biological properties of both the transplanted cells and blood vessels. The rheological component is affected by the ratio of the cell diameter to the capillary size. These dimensional disproportions may be further convoluted by cerebral edema after stroke. The results from this study show that cells as large as 20 to 50 μm (range of mesenchymal cell diameter) are able to bypass the intracerebral entrapment and remain within the systemic vasculature in 17% of animals (Figure 3a). In our study, MSCs were infused into the ipsilateral carotid artery at the completion of the 2-hour ischemic period. The typical MCAO rat model, similar to human stroke, may evolve with significant variability with regard to stroke size, location, and symptom severity. One conceivable explanation for the broad variance in cerebral engraftment in our study is that each individual animal demonstrated a heterogenous timing and pattern of pathophysiological changes. For the animals with no engraftment (Figure 3a and 3b), cell delivery may have been completed before a sufficient cascade of ischemia-related changes occurred to allow subsequent cell engraftment. In the animals with moderate engraftment, recruitment forces were sufficient to attract and anchor a fraction of the grafted cells within the cerebral microvessels, whereas in the high engraftment group, these chemotactant forces, and possibly other factors such as brain edema, caused excessive cell accumulation and compromised microvascular circulation. In the latter group, cells were rarely found to have entered the other hemisphere, indicating near complete trapping; in the moderate engraftment group, however, a substantial proportion of cells was able to cross into the other hemisphere.

In conclusion, IA delivery of stem cells offers the advantage of directly targeting the damaged tissue, and circumvents the problem of cell trapping in filtering organs such as the lung, liver, or spleen. However, it needs to be emphasized that the IA delivery represents a paradox, as the goal is to achieve a high cellular engraftment without inducing microvascular occlusions and compromising cerebral blood flow. In this article we have demonstrated that despite the benefits of intraarterial delivery of stem cells to the ischemic brain, there is a clear risk of vascular occlusion. Thus, noninvasive monitoring methods as described in this study are mandatory for possible clinical translation of IA stem cell delivery in stroke patients.

Acknowledgments
We are grateful to Dr. Miroslaw Janowski for his valuable input and to Mary McAllister for editorial assistance.

Sources of Funding
This work was supported by NIH RO1 NS045062 and a grant from Osiris Therapeutics Inc.

Disclosures
Mark Pittenger and Randall Young own stock in Osiris Therapeutics.

References


Dual-Modality Monitoring of Targeted Intraarterial Delivery of Mesenchymal Stem Cells After Transient Ischemia

Piotr Walczak, Jian Zhang, Assaf A. Gilad, Dorota A. Kedziorek, Jesus Ruiz-Cabello, Randell G. Young, Mark F. Pittenger, Peter C.M. van Zijl, Judy Huang and Jeff W.M. Bulte

Stroke. published online March 6, 2008;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/early/2008/03/06/STROKEAHA.107.502047.citation